Processing

Please wait...

Settings

Settings

Goto Application

1. WO2021045279 - BIOMARKER-BASED THERAPEUTIC COMPOSITION

Publication Number WO/2021/045279
Publication Date 11.03.2021
International Application No. PCT/KR2019/011570
International Filing Date 06.09.2019
IPC
C07D 495/04 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
495Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
02in which the condensed system contains two hetero rings
04Ortho-condensed systems
A61K 31/4365 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
4353ortho- or peri-condensed with heterocyclic ring systems
4365the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
C07K 16/28 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
A61P 35/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
CPC
A61K 31/4365
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
4353ortho- or peri-condensed with heterocyclic ring systems
4365the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
A61P 35/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
C07D 495/04
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
495Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
02in which the condensed system contains two hetero rings
04Ortho-condensed systems
C07K 16/28
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
Applicants
  • 웰마커바이오 주식회사 WELLMARKER BIO CO., LTD. [KR]/[KR]
Inventors
  • 홍승우 HONG, Seung-Woo
  • 문재희 MOON, Jai-Hee
  • 신재식 SHIN, Jae-Sik
  • 김요셉 KIM, Joseph
  • 박윤선 PARK, Yoon-Sun
  • 이민기 LEE, Min-Ki
  • 정준의 JEONG, Joon-Yee
  • 이소희 LEE, So-Hee
  • 최순진 CHOI, Soon-Jin
Agents
  • 제일특허법인(유) FIRSTLAW P.C.
Priority Data
Publication Language Korean (KO)
Filing Language Korean (KO)
Designated States
Title
(EN) BIOMARKER-BASED THERAPEUTIC COMPOSITION
(FR) COMPOSITION THÉRAPEUTIQUE À BASE DE BIOMARQUEURS
(KO) 바이오마커 기반 치료용 조성물
Abstract
(EN)
The present invention provides an anticancer drug for treating patients resistant to protein kinase, the drug comprising a thienopyridine derivative compound or a pharmaceutically acceptable salt thereof as an active ingredient. Here, the patients may be patients with an active RON. In addition, the patient may be patients with a normal KRAS. In addition, the anticancer drug can be applied to patients who have resistance to EGFR inhibitors. In particular, the anticancer drug can be effectively used for treating patients who are resistant to cetuximab treatment.
(FR)
La présente invention concerne un médicament anticancéreux pour le traitement de patients résistant à la protéine kinase, le médicament comprenant un composé dérivé de thiénopyridine ou un sel pharmaceutiquement acceptable de celui-ci en tant que principe actif. Les patients peuvent être des patients ayant un RON actif. Les patients peuvent également être des patients présentant un KRAS normal. De plus, le médicament anticancéreux peut être utilisé chez des patients présentant une résistance aux inhibiteurs d'EGFR. En particulier, le médicament anticancéreux peut être utilisé de manière efficace pour traiter des patients qui sont résistants au traitement par le cétuximab.
(KO)
본 발명은 티에노피리딘 유도체 화합물 또는 이의 약학적으로 허용가능한 염을 유효성분으로 포함하는 단백질 키나제에 내성인 환자 치료용 항암제를 제공한다. 이때, 상기 환자는 활성을 RON을 가지는 환자일 수 있다. 또한, 상기 환자는 정상형 KRAS를 가지는 환자일 수 있다. 또한, 상기 항암제는 EGFR 억제제에 내성을 가지는 환자에 적용될 수 있다. 특히, 상기 항암제는 세툭시맙 치료제에 내성이 있는 환자의 치료에 유용하게 사용될 수 있다.
Also published as
EP2019925556
Latest bibliographic data on file with the International Bureau